201 related articles for article (PubMed ID: 23056398)
41. Low bone mineral density in achondroplasia and hypochondroplasia.
Matsushita M; Kitoh H; Mishima K; Kadono I; Sugiura H; Hasegawa S; Nishida Y; Ishiguro N
Pediatr Int; 2016 Aug; 58(8):705-8. PubMed ID: 26716907
[TBL] [Abstract][Full Text] [Related]
42. [Cytokines in bone diseases. FGF receptor signaling and achondroplasia/hypochondroplasia].
Tanaka H
Clin Calcium; 2010 Oct; 20(10):1490-6. PubMed ID: 20890030
[TBL] [Abstract][Full Text] [Related]
43. HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
Ota S; Zhou ZQ; Romero MP; Yang G; Hurlin PJ
Hum Mol Genet; 2016 Oct; 25(19):4227-4243. PubMed ID: 27506979
[TBL] [Abstract][Full Text] [Related]
44. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.
Pannier S; Mugniery E; Jonquoy A; Benoist-Lasselin C; Odent T; Jais JP; Munnich A; Legeai-Mallet L
Bone; 2010 Nov; 47(5):905-15. PubMed ID: 20673820
[TBL] [Abstract][Full Text] [Related]
45. The extracellular domain of fibroblast growth factor receptor 3 inhibits ligand-independent dimerization.
Chen L; Placone J; Novicky L; Hristova K
Sci Signal; 2010 Nov; 3(150):ra86. PubMed ID: 21119106
[TBL] [Abstract][Full Text] [Related]
46. Chimeras of the native form or achondroplasia mutant (G375C) of human fibroblast growth factor receptor 3 induce ligand-dependent differentiation of PC12 cells.
Thompson LM; Raffioni S; Wasmuth JJ; Bradshaw RA
Mol Cell Biol; 1997 Jul; 17(7):4169-77. PubMed ID: 9199352
[TBL] [Abstract][Full Text] [Related]
47. Analysis of the FGFR3 gene in Japanese patients with achondroplasia and hypochondroplasia.
Katsumata N; Mikami S; Nagashima-Miyokawa A; Nimura A; Sato N; Horikawa R; Tanae A; Tanaka T
Endocr J; 2000 Mar; 47 Suppl():S121-4. PubMed ID: 10890199
[TBL] [Abstract][Full Text] [Related]
48. In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia.
Gonçalves D; Rignol G; Dellugat P; Hartmann G; Sarrazy Garcia S; Stavenhagen J; Santarelli L; Gouze E; Czech C
PLoS One; 2020; 15(12):e0244368. PubMed ID: 33370388
[TBL] [Abstract][Full Text] [Related]
49. Skeletal Characterization of the Fgfr3 Mouse Model of Achondroplasia Using Micro-CT and MRI Volumetric Imaging.
Shazeeb MS; Cox MK; Gupta A; Tang W; Singh K; Pryce CT; Fogle R; Mu Y; Weber WD; Bangari DS; Ying X; Sabbagh Y
Sci Rep; 2018 Jan; 8(1):469. PubMed ID: 29323153
[TBL] [Abstract][Full Text] [Related]
50. Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia.
Matsushita M; Mishima K; Esaki R; Ishiguro N; Ohno K; Kitoh H
J Neurosurg Pediatr; 2017 Jan; 19(1):91-95. PubMed ID: 27767902
[TBL] [Abstract][Full Text] [Related]
51. The pathogenic A391E mutation in FGFR3 induces a structural change in the transmembrane domain dimer.
Mudumbi KC; Julius A; Herrmann J; Li E
J Membr Biol; 2013 Jun; 246(6):487-93. PubMed ID: 23727984
[TBL] [Abstract][Full Text] [Related]
52. Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis.
Su N; Sun Q; Li C; Lu X; Qi H; Chen S; Yang J; Du X; Zhao L; He Q; Jin M; Shen Y; Chen D; Chen L
Hum Mol Genet; 2010 Apr; 19(7):1199-210. PubMed ID: 20053668
[TBL] [Abstract][Full Text] [Related]
53. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
[TBL] [Abstract][Full Text] [Related]
54. [Differentiation of achondroplasia and other similar genetic dwarfism by FGFR3 gene analysis].
Zhang Y; Yu W; Shen M; Fang Q; Fan M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Aug; 17(4):252-5. PubMed ID: 10932008
[TBL] [Abstract][Full Text] [Related]
55. Primary and secondary dimer interfaces of the fibroblast growth factor receptor 3 transmembrane domain: characterization via multiscale molecular dynamics simulations.
Reddy T; Manrique S; Buyan A; Hall BA; Chetwynd A; Sansom MS
Biochemistry; 2014 Jan; 53(2):323-32. PubMed ID: 24397339
[TBL] [Abstract][Full Text] [Related]
56. An induced pluripotent stem cell line (GZHMCi004-A) derived from a fetus with heterozygous G380R mutation in FGFR3 gene causing achondroplasia.
Li N; Lin SM; Li Y; Sun J; Zhang L; Chen M
Stem Cell Res; 2021 May; 53():102322. PubMed ID: 33848795
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
Lorget F; Kaci N; Peng J; Benoist-Lasselin C; Mugniery E; Oppeneer T; Wendt DJ; Bell SM; Bullens S; Bunting S; Tsuruda LS; O'Neill CA; Di Rocco F; Munnich A; Legeai-Mallet L
Am J Hum Genet; 2012 Dec; 91(6):1108-14. PubMed ID: 23200862
[TBL] [Abstract][Full Text] [Related]
58. [Clinical features and
Zhang HQ; Tao DY; Zhang JJ; Niu HH; Luo JF; Cheng SQ
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Apr; 24(4):405-410. PubMed ID: 35527416
[TBL] [Abstract][Full Text] [Related]
59. Ser217Cys mutation in the Ig II domain of FGFR3 in a Chinese family with autosomal dominant achondroplasia.
Zhang SR; Zhou XQ; Ren X; Wang TT; Yuan MX; Wang Q; Liu JY; Liu MG
Chin Med J (Engl); 2007 Jun; 120(11):1017-9. PubMed ID: 17624273
[No Abstract] [Full Text] [Related]
60. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.
Monsonego-Ornan E; Adar R; Feferman T; Segev O; Yayon A
Mol Cell Biol; 2000 Jan; 20(2):516-22. PubMed ID: 10611230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
